Eli Lilly and Company

Indiana University

John Philip Mayer

Richard Dennis DiMarchi

Paul Leslie Ornstein

Michael J Martinelli

David L Smiley

Matthew Joseph Fisher

Jorge Alsina-Fernandez

Larry W Hertel

Qing Shi

Karin Briner

Wolfgang Glaesner

Rohn Lee Millican, Jr

Timothy Ivo Richardson

Lili Guo

Zhipei Wu

Lianshan Zhang

Vincent Mancuso

Christopher William Doecke

Binbin Kou

Chaoyu Xie

Andrew Mark Vick

Fa Liu

Jikesh Arvind Shah

Christopher Kelly Biggers

Krister Bengt Bokvist

Fa Zhang

Piotr Mroz

Richard D Dimarchi

Rohn Lee Junior Millican

Modified glucagon peptides are disclosed having improved solubility and/or stability while retaining glucagon agonist activity. The glucagon peptides have been modified by the substitution of pyridyl-alanine for a native amino acid at one or more of positions 6, 10 or 13 and/or substitution with an amino acid in the D-conformation at position 20 or 21 compared to native glucagon.

Aqueously soluble and chemically stable glucagon peptides

Prodrug formulations of insulin and insulin analogs are provided wherein the insulin peptide has been modified by an amide bond linkage of a dipeptide prodrug element. The prodrugs disclosed herein have extended half-lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.

Lipidated amide-based insulin prodrugs

Disclosed herein are insulin agonist peptides conjugated to incretins wherein the incretin-insulin conjugate has agonist activity at the insulin receptor and the corresponding incretin receptor, and stimulates weight loss in an individual administered the compound.

Incretin-insulin conjugates

The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide-1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analogs with amino acid substitutions introduced to modulate activity for both GIP-R and GLP-1-R and maintain selectivity over Gluc-R.

Peptides and methods for their preparation and use

The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (&#x3b2;) cell population, or decreasing gastric or intestinal motility.

GLP-1 pegylated compounds

The present invention relates to melanocortin receptor agonists of formula (I), which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction 

Melanocortin receptor agonists

Growing community of inventors

Indianapolis, IN, United States of America

John Philip Mayer